Trial
NCT04204941
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Phase ITERMINATEDREGULATORYConfidence: HIGH
Sponsor
Epizyme, Inc.
Collaborators
—
Condition
Advanced Soft-tissue Sarcoma
Intervention
Tazemetostat
Why stopped
FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required enrolment targets. No safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-07